Tamtam Try Tamtam free
argenx logo

argenx account plan

Developing antibody-based medicines

At a glance

argenx is a Dutch-Belgian immunology biotech selling VYVGART, the first approved FcRn blocker: $4.2 billion FY2025 product net sales, 1,863 employees.

argenx SE is a European company with its seat in Amsterdam and its principal offices and R&D in Zwijnaarde, Belgium, that discovers and sells antibody-based medicines for severe autoimmune diseases. Its only marketed product is the VYVGART franchise (efgartigimod), approved for generalized myasthenia gravis (gMG) and CIDP in more than 30 countries and sold mainly in the United States through its own sales force, with Zai Lab as partner in Greater China. FY2025 product net sales were $4.2 billion, up 90%, and profit for the year was $1.3 billion, its first year of operational profitability. It had 1,863 employees at end-2025, outsources manufacturing to Lonza and Fujifilm, and has been led by CEO Karen Massey since May 2026.

Business units

Strategic priorities

Vision 2030
Treat 50,000 patients, secure 10 labeled indications and advance five pipeline candidates into Phase 3 by 2030.
More VYVGART patients
Expand VYVGART through label expansions such as all gMG serotypes and ocular MG, new presentations like the prefilled syringe and a 2027 autoinjector, and myositis as the entry into rheumatology.
Future of FcRn medicines
Shape the long-term future of FcRn with next-generation molecules ARGX-213 and ARGX-124, an oral FcRn program, new delivery modalities and combinations.
Next wave of immunology
Diversify beyond FcRn, led by empasiprubart, and add novel biology through business development with biotechs as well as academic partners.
Keep the argenx way
Teams are organised by indication area rather than functional silos to avoid hierarchy and bureaucracy while the company scales.

Latest results

In H1 2026 (six months to June 30, 2026) VYVGART product net sales were $2,813 million against $1,739 million in H1 2025, and operating profit rose to $887 million from $340 million; profit for the period was $838 million. The United States contributed $2,380 million, Japan $169 million and the rest of the world $247 million. In Q2 2026 alone product net sales were $1.5 billion, up 60% year over year and the 18th consecutive quarter of growth, while combined R&D and SG&A stepped up to $903 million. Cash and cash equivalents were $3,584 million plus $1,600 million of current financial assets at June 30, 2026.

Investments and deals

Forte Biosciences acquisition
argenx completed the $2.2 billion acquisition of Forte Biosciences, as cited by PharmaVoice in August 2026.
R&D spending
R&D expenses were $1,364,132 thousand in FY2025 (+39%) and $929 million in H1 2026, funding registrational studies of efgartigimod, empasiprubart and adimanebart.
Manufacturing capacity
The Fujifilm partnership expanded in 2025 to a North Carolina site; commercial supply commitments with Lonza and Fujifilm total approximately $1.2 billion.
Commercial build-out
SG&A grew 30% in 2025 to scale VYVGART commercial operations, and argenx is preparing to expand its field force for a myositis launch.

Challenges and risks

Single-product dependence
All product sales come from VYVGART, and competition in gMG and CIDP is intense, with competitors including AstraZeneca, AbbVie, Amgen, Johnson & Johnson and Novartis.
Customer concentration
Three U.S. customers represented approximately 72% of product net sales in H1 2026.
U.S. pricing reform
IRA Medicare negotiation, inflation rebates, Part D redesign and state price controls are named risks for a business that is mainly U.S.-weighted.
Exclusivity and biosimilars
Base regulatory exclusivity is expected until December 2033 in the U.S. and August 2032 in the EU, and EU pharmaceutical reform is likely to shorten baseline market exclusivity.
Reliance on third parties
Manufacturing, clinical research and distribution depend on CROs, contract manufacturers and partners such as Zai Lab, with tariff and U.S.-China trade risk.

What leadership says

“Similar to Keytruda, it's a once-in-a-generation asset that acts as a backbone therapy that allows us to build on it.”

Karen Massey, Chief Executive Officer · PharmaVoice First 90 Days interview (August 28, 2026)

“Our strategy in general is that we're not just an FcRn company. Our goal is to become an immunology innovator and transform the lives of immunology patients more broadly.”

Karen Massey, Chief Executive Officer · PharmaVoice First 90 Days interview (August 28, 2026)

“VYVGART has the potential to have a similar impact in rheumatology as it has had in neurology. Autoimmune myositis is our entry point.”

Karen Massey, Chief Executive Officer · argenx Q2 2026 earnings call (July 23, 2026)

“it has to be novel biology, and it has to be in areas where there is significant unmet patient need.”

Karen Massey, Chief Executive Officer · On business development, argenx Q2 2026 earnings call (July 23, 2026)

Where a supplier can help

Launch readiness in rheumatology
The myositis launch, engagement with 650 KOLs and a field force expansion create demand for medical affairs, commercial analytics and HCP engagement services.
Clinical trial execution
Multiple registrational readouts and ten molecules in clinic by end-2026 rely on CROs and trial technology, an opening for clinical operations and data vendors.
Manufacturing and device supply
Outsourced manufacturing with about $1.2 billion of supply commitments and the 2027 autoinjector launch point to CDMO, fill-finish and device partners.
Patient access and market access
U.S. pricing reform and payer coverage of new labels such as seronegative gMG call for market access, reimbursement and patient support services.
AI for internal operations
The CEO uses an AI agent daily and argenx runs AI-built innovation dashboards; AI tools that cut reporting overhead fit its fight against bureaucracy.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like argenx?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about argenx

What does argenx do?

argenx discovers and sells antibody-based medicines for severe autoimmune diseases; its marketed product is VYVGART (efgartigimod), the first approved FcRn blocker, for gMG, CIDP and ITP in Japan.

What is argenx's revenue?

FY2025 product net sales were $4.2 billion, up 90%, and H1 2026 product net sales were $2,813 million.

How many employees does argenx have?

argenx had 1,863 employees at end-2025, including 789 in the U.S. and 565 in Belgium.

Who leads argenx?

Karen Massey became CEO in May 2026, succeeding co-founder Tim Van Hauwermeiren, who became non-executive chair; Karl Gubitz is CFO.

What is argenx's strategy?

Under Vision 2030 argenx aims to treat 50,000 patients in 10 labeled indications and bring five candidates into Phase 3, growing VYVGART while diversifying its immunology pipeline beyond FcRn.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)